Bothell Facility at Forefront of Personalized Cell Therapy

Bristol Myers Squibb’s Bothell manufacturing facility has been designated as one of the production facilities for the company’s newly-approved cancer treatment, Breyanzi. The facility has already begun production on the CAR T cell therapy used to treat a type of lymphoma and is one of five cell therapy manufacturing facilities that BMS runs.

In addition to its Bothell location, Bristol Myers Squibb has around 1,000 employees at its offices in downtown Seattle that aid the company’s discovery, pipeline development, and translational research efforts focused on cell therapy and immuno-oncology. Researchers there also conduct extensive exploratory translational studies to support clinical studies and inform asset development strategies.